Search bioRxiv⌕ Search

Biology subjects

Leung, C. S. K.

Publications and source records attributed to Leung, C. S. K..

4 recordsLinked to original sources

Vaccination targeting the novel endogenous tumor-associated antigen Gpr149 induces protective immunity against checkpoint inhibitor-refractory SB28 glioblastoma

Background: Glioblastoma is a lethal brain tumor notable for its limited spontaneous induction of CD8+ T cell responses. Vaccination may overcome this limitation by generating tumor-specific CD8+ T cells capable of mediating anti-tumor immunity in the brain. However, preclinical vaccine development is constrained by a lack of immunologically stringent glioblastoma models with defined endogenous antigens. We therefore sought to identify endogenous, vaccine-targetable antigens expressed by the immune checkpoint-refractory SB28 syngeneic mouse glioblastoma model and to evaluate their targetability using a heterologous prime-boost regimen with the chimpanzee adenovirus ChAdOx1 and the modified vaccinia Ankara (MVA) viral vector-based vaccines. Methods: RNA sequencing and whole-exome sequencing were used to identify candidate tumor-associated antigens (TAAs) and neoantigens, and tumor-specific expression was validated by RT-qPCR. ChAdOx1 and MVA vectors encoding candidate antigens were generated and evaluated for immunogenicity and anti-tumor efficacy. Antigen-specific CD8+ T cell responses and minimal epitopes were characterized by ex vivo restimulation, MHC-I binding assays, tetramer staining, and tumor cytotoxicity assays. Results: We identified five candidate TAAs (Gpr149, Cdh6, Fbn2, Igf2bp1, and Shox2) but no suitable neoantigen targets in SB28. Vaccination induced CD8+ T cell responses against the candidate TAAs, and immunogenic minimal epitopes were identified for each. Among the candidates, Gpr149 elicited the strongest vaccine-induced CD8+ T cell responses. In mice challenged intracranially with SB28, Gpr149-targeted ChAdOx1/MVA vaccination combined with immune checkpoint blockade significantly prolonged median survival and resulted in long-term survival in 50% of mice, whereas vaccination targeting the other TAAs did not improve survival. CD8+ T cells recognizing the immunodominant Gpr149128-135 epitope (VCYNFYTM) specifically recognized and lysed wild-type SB28 cells, but not Gpr149-knockout SB28 cells, confirming endogenous processing and presentation of the targeted epitope. Conclusions: Gpr149 is an endogenous SB28 tumor antigen that can be effectively targeted by ChAdOx1/MVA vaccination to generate protective anti-tumor immunity against intracranial glioblastoma. Protection was associated with a dominant CD8+ T cell response to the Gpr149128-135 epitope VCYNFYTM. These findings establish endogenously expressed Gpr149 in SB28 as a physiologically relevant model for evaluating antigen-targeted immunotherapies and provide a systematic approach for identifying endogenous vaccine targets in other preclinical models.

immunology↗

CXCR3 on transferred T cells enables vaccine-boosted adoptive T-cell therapy in solid tumors

Adoptive T-cell therapy (ACT) has demonstrated marked clinical benefit in hematological malignancies but has limited efficacy against solid tumors. Cancer vaccines can improve ACT, but the mechanisms underlying this combination are poorly understood. Here, we combined ACT with chimpanzee adenovirus ChAdOx1 (ChAd) and modified vaccinia Ankara (MVA) encoding tumor antigens. Whereas PD1 blockade failed to improve ACT, the combination with ChAd/MVA vaccination drove durable regression of established tumors, correlating with expansion of tumor-reactive T cells in lymphoid organs and increased tumor infiltration by T cells. Mechanistically, ChAd priming induced CXCR3 ligands (CXCL10 and CXCL9) in the vaccine-draining lymph node, thereby recruiting transferred T cells to this node independently of cognate antigen. CXCR3 expression on the transferred T cells, but not on host cells, was required for the anti-tumor effect of the combination therapy and favored T-cell accumulation in the vaccine-draining lymph node and the tumor. These findings identify CXCR3 on the transferred T cells as a determinant of ACT plus vaccination synergy and provide a rationale for combining viral-vector vaccines with TCR-T therapies, and for selecting or engineering T cells to retain CXCR3 expression.

immunology↗

Systemic viral vector vaccination induces brain resident memory T cells to drive anti-glioblastoma immunity

Glioblastoma is a lethal brain tumor that is unresponsive to current cancer immunotherapeutic approaches, including immune checkpoint blockade (ICB). This suggests that initial priming of T cells, rather than their expansion and licensing as effectors, is a restricting feature in this tumor setting. To overcome the limited initiation of CD8+ T cell responses, we employed a strong heterologous prime-boost vaccination with the simian adenovirus ChAdOx1 and poxvirus modified vaccinia Ankara (MVA). Vaccination conferred therapeutic efficacy against orthotopic, immune checkpoint-blockade (ICB)-refractory SB28 murine glioblastoma. Vaccination was effective against both the murine tumor antigen, P1A, and a newly identified glioblastoma-associated antigen, Gpr149. Additional treatment with ICB provided no additional benefit. Systemic ChAdOx1/MVA vaccination induced robust infiltration of antigen-specific T cells in tumor-challenged brains, the majority of which exhibited a CD103+CD69+CD8+ tissue-resident memory (TRM)-like phenotype. These cells were polyfunctional, durable in brains with sustained tumor control, and mediated tissue-specific immunological memory. Moreover, intracranial adoptive transfer of glioblastoma-derived antigen-specific TRM-like cells was sufficient to protect naive recipients from subsequent orthotopic tumor challenge. Together, these findings establish that viral vector vaccination can generate tumor-specific TRM-like cells that mediate effective anti-glioblastoma immunity, providing a rationale for clinical evaluation of ChAdOx1/MVA-based strategies in glioblastoma.

immunology↗

Chemotherapy synergizes with cancer vaccines and expands stem-like TCF1+CD8+ T cells

Therapeutic cancer vaccines, whether based on neoantigens or shared antigens, will likely be given in the clinic together with the standard of care, which often comprises immune checkpoint blockade therapy and chemotherapy. It remains unclear, however, whether vaccines effectively synergize with chemotherapy. Here, we tested the combination of a heterologous prime-boost viral vector vaccine with chemotherapy (CarboTaxol) and anti-PD- 1. We show that this triple combination improves tumor control and survival in different murine tumor models. CarboTaxol, and also cyclophosphamide, acted as an immune adjuvant for the vaccines, enhancing tumor-specific CD8+ T-cell responses, irrespective of the presence of a tumor. These chemotherapies expanded stem-like T cell factor 1 (TCF1)+CD8+ T cells. Inhibition of the transcriptional activity of TCF1/{beta}-catenin with a small molecule inhibitor abolished the immune adjuvant effect of CarboTaxol. This study sheds light on the new immunomodulatory roles of chemotherapies and holds promises for clinical testing of this combination strategy. HighlightsO_LIThe combination of CarboTaxol with viral vector cancer vaccines and anti-PD-1 promotes better tumor control, tumor clearance, and survival C_LIO_LICarboTaxol increases TCF1 expression in CD8+ T cells and expands stem-like TCF1+CD8+ T cells C_LIO_LICarboTaxol acts as an adjuvant for cancer vaccines irrespective of the presence of a tumor and this effect is mediated by TCF1/{beta}-catenin activity C_LI

immunology↗